Delivery Order SPE2DB22D3301-SPE2DB26FX3NC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,673.08 to AmerisourceBergen Drug Corp for the supply of Hemlibra 105 mg/0.7 mL vials. This firm fixed-price, non-set-aside contract was executed on May 30, 2025, with an ultimate completion date of June 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Hemlibra is a bispecific monoclonal antibody used in the treatment of hemophilia A and B, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $26,451.57 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 150 mg/ml vials. This firm fixed price contract, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the pharmaceutical distributor maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of HEMLIBRA 105 mg/0.7 mL vials totaling $6,168.26. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award authority. The order is scheduled for completion by August 29, 2025, with performance taking place at AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania. HEMLIBRA is a specialty pharmaceutical product...
- The Defense Logistics Agency awarded a $35,268.76 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of HEMLIBRA 150 mg/ml vials. This non-competitive delivery order, with an ultimate completion date of June 3, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 master pharmaceutical supply vehicle running through December 2026. The performance...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEMLIBRA 150 MG/ML vial, a medication, with a ceiling value of $8,817.19 and a period of performance through July 7, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that AmerisourceBergen holds with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,673.08 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 105 mg/0.7 ml vials. This is a firm fixed-price, non-set-aside contract with a completion date of August 8, 2025, and was awarded on July 18, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order operates under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $34,564.08 firm fixed-price delivery order is for the supply of HEMLIBRA 150 MG/ML VIALML, a critical medical product, with a period of performance through January 22, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,673.08, is for the supply of 4567331942 HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a specialty medication. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,673.08, is for the delivery of HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a prescription medication. The contract has an ultimate completion date of May 29, 2025. AmerisourceBergen Drug Corp is the prime contractor on this award and holds a significant Indefinite Delivery Contract (IDC)...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,336.54 firm fixed-price delivery order contract is for the supply of HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a specialty medication. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX3NCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Hemlibra 105 mg/0.7 mL vials, a specialty pharmaceutical product used in hemophilia treatment. This competitively awarded, firm fixed-price delivery order has a ceiling value of $6,168.26 and is scheduled for completion by November 10, 2025. The contract is not set-aside and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. That prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates its established capability to fulfill specialized medical procurement requirements for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 10/20/25 |